Lionco Pharmaceutical Group Co Ltd
SSE:603669
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Lionco Pharmaceutical Group Co Ltd
Interest Income Expense
Lionco Pharmaceutical Group Co Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lionco Pharmaceutical Group Co Ltd
SSE:603669
|
Interest Income Expense
-¥31m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-66%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Interest Income Expense
-¥19.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Interest Income Expense
¥484.8m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
12%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Interest Income Expense
¥1.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
39%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Interest Income Expense
¥109.8m
|
CAGR 3-Years
59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Interest Income Expense
¥258.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Lionco Pharmaceutical Group Co Ltd
Glance View
Lionco Pharmaceutical Group Co., Ltd. engages in the sale of chemical drug and antibiotic agents. The company is headquartered in Shannan, Xizang and currently employs 678 full-time employees. The company went IPO on 2015-05-28. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The firm's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The firm operates its business in domestic market.
See Also
What is Lionco Pharmaceutical Group Co Ltd's Interest Income Expense?
Interest Income Expense
-31m
CNY
Based on the financial report for Sep 30, 2025, Lionco Pharmaceutical Group Co Ltd's Interest Income Expense amounts to -31m CNY.
What is Lionco Pharmaceutical Group Co Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
-66%
Over the last year, the Interest Income Expense growth was -68%.
